Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 27,493 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now owns 458,506 shares of the company’s stock, valued at $7,592,859.36. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tyra Biosciences Stock Down 1.7 %

Shares of NASDAQ TYRA opened at $16.39 on Friday. The business has a fifty day moving average price of $22.51 and a two-hundred day moving average price of $19.87. Tyra Biosciences, Inc. has a fifty-two week low of $10.60 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.09. As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors have recently modified their holdings of the business. Oppenheimer & Co. Inc. acquired a new position in shares of Tyra Biosciences during the 1st quarter worth $977,000. Vanguard Group Inc. raised its holdings in shares of Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after buying an additional 145,346 shares in the last quarter. Perceptive Advisors LLC raised its holdings in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in shares of Tyra Biosciences during the 2nd quarter worth $3,047,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Oppenheimer boosted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Piper Sandler assumed coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. HC Wainwright boosted their price target on Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.40.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.